Postprandial hyperglycemia: Treating its atherogenic potential;Hiperglicemia pós-prandial: Tratamento do seu potencial aterogênico

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 5, 2006, Pages

  Geloneze, Bruno ^a   Lamounier, Rodrigo Nunes ^b,c   Coelho, Otávio Rizzi ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FMUSP ^*  (Brazil)

Author keywords

Atherogenesis; Cardiovascular risk; Postprandial glycemia; Postprandial treatment; Prandial state

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 NITROTYROSINE; ACARBOSE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; EXENDIN 4; GINSENG EXTRACT; GLIBENCLAMIDE; GLICLAZIDE; GLIFAGE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLP 1 RECEPTOR AFFECTING AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HUMAN INSULIN; INSULIN; INSULIN LISPRO; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; NITRIC OXIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ARTERY WALL; ATHEROGENESIS; BEHAVIOR THERAPY; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC PATIENT; DIET THERAPY; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENDOTHELIAL DYSFUNCTION; EXERCISE; GASTROINTESTINAL SYMPTOM; GINSENG; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; KINESIOTHERAPY; LIPID METABOLISM; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; PHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EXERCISE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 33846369855     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2006001800018     Document Type: Review

References (115)

1. De Fronzo RA. Lilly lecture 1987. The triumvirate: beta cell, muscle, liver. A collusion responsible for IDDM. Diabetes 1988; 37: 667-87.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
3. American Diabetes Association. Standards of care for patients with diabetes mellitus (Position Statement). Diabetes Care 2004 (Suppl 1): S15-35.
4. DECODE Study Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001; 161: 397-405.
5. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin dependent diabetes mellitus. N Engl J Med 1992; 327: 707-13.
6. Gavin III JR. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001; 88(suppl 1): 4H-8H.
7. Lebovitz HE. A Symposium: Managing the atherogenic potential of the postprandial state. Am J Cardiol 2001; 88(Suppl 1): 1H-3H.
8. Meyer U, Gressner A M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clinical Chemistry 2004; 50(9): 1511-25.
9. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-39.
10. Service FJ, Hall LD, Westland RE, et al. Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 1983; 25: 316-21.
11. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003; 46(10): 1297-12.
12. Kahn SE. The importance of beta-cell in the pathogenesis of type 2 diabetes melitus. Am J Med 2000; 108: 2S-8S.
13. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-42.
14. McKillop AM, Abdel-Wahab YH, Mooney MH, et al. Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity. Diabetes Metab 2002; 28: 3S61-69.
15. Visboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004; 47(3): 357-66.
16. Bruce DG, Storlien LH, Furler SM, Chisholm DJ. Cephalic phase metabolic responses in normal weight adults. Metabolism 1987; 36: 721-5.
17. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-9.
18. Luzi L, De Fronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989; 257: E241-E246.
19. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989; 38: 550-7.
20. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002; 51(Suppl 1): S109-16.
21. Weyer C, Borgadus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
22. Freskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 2001; 54: 869-76.
23. Haffner SM, Lehto S, Ronnemma T, et al. Mortality from coronary artery disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
24. Avezum A, Piegas LS, Pereira JCR. Risk factors associated with acute miocardial infarction in the São Paulo metropolitan region. A developed region in a developing country. Arq Bras Cardiol 2005; 84(3): 206-13.
25. Moraes SA, de Souza JM. Diabetes Mellitus and ischemic heart disease. Comparison by gender. Arq Bras Cardiol 1996; 66(2): 59-63.
26. Matsubara BB, Okoshi K, Okoshi MP, et al. Arterial dysfunction as a possible mechanism of cardiac injury in type. A Doppler-echocardiographic study. Arq Bras Cardiol 1997; 69(3): 155-9.
27. Kannel WB, McGee DL. Diabetes and cardivascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
28. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Interventional Trial. Diabetes Care 1993; 16: 434-44.
29. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000; 23: 962-68.
30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
31. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
32. De Vegt F, Dekker JM, Ruhè HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-31.
33. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36: 689-92.
34. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-40.
36. Fuller JH, Shipley MJ, Rose G et al. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 1980; 8183: 1373-76.
37. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32(5): 300-4.
38. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2(2): 131-41.
39. Bahia L, Gomes MB, da Cruz P di M, Gonçalves M de F. Coronary artery disease, microalbuminuria and lipid profile in patients with non-insulin dependent diabetes mellitus. Arq Bras Cardiol 1999; 73(1): 11-22.
40. Zilversmidt DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-85.
41. Groot PHE, Van Stiphout WAHJ, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991; 11: 653-62.
42. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-45.
43. Mamo JCL, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998; 141(suppl): S63-69.
44. Miesenböck G, Patsch JR. Postprandial hyperlipidemia: the search for the atherogenic lipoprotein. Curr Opin Lipidol 1992; 3: 196-201.
45. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 1991; 14: 839-55.
46. Ginsberg HN. Lipoprotein physiology. Endocrinol Metabol Clin North Am 1998; 27: 503-19.
47. Pastch J. Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Eur Heart J 1998; 19(suppl H): H2-H6.
48. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common on patients with diabetes mellitus.Am J Cardiol 2001; 11(suppl.): 4H-8H.
49. Daughert YA, Lange LG, Sobel BE, Schonfeld G. Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. J lipid Res 1985; 16: 955-63.
50. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosortion from human atherosclerotic plaque. Artherioscler Thromb 1994; 14: 1767-74.
51. Cohn, J S. Oxidized fat in the diet, postprandial lipaemia and cardiovascular disease. Current Opinion in Lipidology 2002; 13(1): 19-24.
52. Frayn KN. Insulin resistance, impaired postprandial lipid metabolism and abdominal obesity. A deadly triad. Med Princ Pract 2002; 11(suppl 2): 31-40.
53. Lebovitz HE. Effect of the postprandial state on nontraditional risk factors.Am J Cardiol 2001; 88(suppl): 20H-25H.
54. Haller H. Postprandial glucose and vascular disease. Diabetic Medicine 1997; 14: S50-S56.
55. Giuliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-90.
56. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-75.
57. Lee IK, Kim HS, Bae JH. Endothelial dysfunction: its relantionship with acute hyperglycemia and hyperlipidemia. Int J Clin Pract 2002; 129(suppl): 59-64.
58. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-73.
59. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001; 103: 1618-23.
60. Ceriello A, Quagliaro L, Piconi L et al. Effect of postprandial hypertrigliceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004; 53: 701-10.
61. Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-91.
62. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes: the possible role of the oxidative stress. Diabetes 1995; 44: 924-8.
63. Sakamoto T, Ogawa H, Kawano H, et al. Rapid change of platelet aggregability in acute hyperglycemia: detection by a novel laser-light scattering method. Thromb Haemost 2000; 83: 475-9.
64. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest 1979; 63: 485-93.
65. Ceriello A, Falleti E, Motz E, et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998; 30: 146-9.
66. Marfella R, Esposito K, Giunta R, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000; 101: 2247-51.
67. Van Osostrom AJHHM, Sijmonsma TP, Verseyden C. Postprandial recruitment of neutrophils may contribuye to endotelial dysfunction. J Lipid Res 2003; 44: 576-83.
68. Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values. Arch Intern Med 2004; 164: 1627-32.
69. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management. Endocr Pract 2002; 8 (Suppl 1): 40-82.
70. Consenso Brasileiro sobre Diabetes 2002. Diagnóstico e classificação do diabetes melito e tratamento do diabetes melito do tipo 2. Rio de Janeiro: Diagraphic Editora; 2003.
71. De Venciana, Major CA, Morgan MA, Tamerou A, Toohey JS, Lien JM, EVANS AT.Postprandial versus preprandial blood glucose monitoring in women with gestacional diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333: 1237-41.
72. Bastyr EJ, Stuart CA, Brodows RG, et al. Therapy Focused on Lowering Postprandial Glucose, Not Fasting Glucose, May be Superior for Lowering HbA1c. Diabetes Care 2000; 23: 1236-41.
73. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26: 881-5.
74. Larsen JJ, Dela F, Kjaer M, Galvo H. The effect of intense exercise on postprandial glucose homeostasis in type 2 diabetic patients. Diabetologia 1999; 42: 1282-92.
75. Poirier P, Mawhinney S, Grondin L, et al. Prior meals enhances the plasma glucose lowering effect exercise in type 2 diabetes. Med Sci Sports Exerc 2001; 33: 1259-64.
76. Gill JMR, Hardman AE. Postprandial lipemia: effects of exercise and restriction of energy intake compared. Am J Clin Nutr 2000; 71: 465-71.
77. Wolever TM, Bolgnesi C. Source and amount of carbohydrate affect postprandial glucose and insulin in normal subjects. J Nutr 1996; 126: 2798-806.
78. Brenelli SL, Campos SDS, Saad MJA. Viscosity of gums in vitro and their ability to reduce postprandial hyperglycemia in normal subjects. Brazilian J Med and Biol Res 1997; 30: 1437-40.
79. Sheard NF, Clark NG, Brand-Miller JC et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes. A Statement by the American Diabetes Association. Diabetes Care 2004; 27(9): 2266-71.
80. Hu FB, Willet WC. Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569-78.
81. Freiberg MS, Cabral HJ, Heeren TC et al. Alcohol Consumption and the prevalence of the Metabolic Syndrome in the U.S. Diabetes Care 2004; 27: 2954-59.
82. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
83. Clark HE, Mattews DR. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996; 28: 445-50.
84. Ashcroft FM. Mechanisms of the glycaemic effercts of sulfonylureas. Horm Metab Res 1996; 28: 456-63.
85. Shapiro ET, Van Cauter E, Tillil H, et al. Glyburide enhances the responsiveness of the beta cell to glucose but does not correct the abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 571-6.
86. Dabrowski M, Wahl P, Holmes WE, Ashcroft FM. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001; 44: 747-56.
87. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-16.
88. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? International Journal of Obesity 2000; 24(Suppl 3): S21-31.
89. Tankova T, Dragomir K, Dakovska L, KiriloVG. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diab Res Clin Pract 2003; 59: 43-9.
90. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-7.
91. Inzucchi SE. Oral Antihyperglycemic Therapy for Type 2 Diabetes. Scientific Review. JAMA 2002; 287: 360-72.
92. Bailey C. Biguanides and NIDD. Diabetes Care 1992; 15(2): 755-72.
93. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-79.
94. Fery F, Plat L, Balasse EO. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997; 46(2): 227-33.
95. UK Prospective Diabetes Study Group. Effect of intensive glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
96. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999; 16: 1-14.
97. Rosen ED, Spiegelman BM. PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-34.
98. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes. Diabetologia 2000; 43: 278-84.
99. Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003; 26(6): 1685-90.
100. Lebovitz HE. Alfa-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Revs 1998; 6: 132-45.
101. Holman RR, Cull CA, Turner RC on Behalf of The UKPDS Study GROUP. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22(6): 960-4.
102. Hirsh IB. Insulin Analogues. N Engl J Med 2005; 352: 174-83.
103. Evans M, Anderson RA, Smith JC, Khan N, et al. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Europ J Clin Invest 2003; 33: 231-8.
104. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171-5.
105. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25(5): 883-8.
106. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28(2): 260-5.
107. Odegard PS, Capoccia KL. Inhaled Insulin: Exubera. Ann Pharmacother 2005; 39: 843-53.
108. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies. JAMA 1999; 281: 2005-12.
109. Vuskan V, Sievenpiper JL, Koo VYY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 2000; 160: 1009-13.
110. Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagons, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003; 26: 1-8.
111. Weyer C, Gottleb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes. Diabetes Care 2003; 26: 3074-9.
112. Edwards CM, Stanley SA, DaVis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-61.
113. Juhl CB, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-9.
114. Kolterman OG, Buse JB., Fineman MS, et al. Synthetic Exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-89.
115. Ahrén BO, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-75.